FDA clears IntraBio's rare disease therapy; Alkermes shares ADHD trial results
The FDA approved Aqneursa, a treatment for ataxia-telangiectasia, developed by privately held IntraBio. Separately, Alkermes disclosed findings from an attention-deficit/hyperactivity disorder study. The announcements highlight progress in rare disease and neuropsychiatric drug development.
The U.S. Food and Drug Administration has granted approval to Aqneursa, a therapy created by privately held IntraBio for individuals living with ataxia-telangiectasia, a rare inherited disorder affecting coordination and immune function. This regulatory milestone offers a new treatment option for a condition with limited existing therapies.
In a separate development, Alkermes has released findings from a clinical study evaluating a potential treatment for attention-deficit/hyperactivity disorder. The disclosure adds to a growing pipeline of neuropsychiatric candidates. Together, these announcements underscore ongoing momentum across both rare disease and mental health drug development, areas where patient needs remain substantial.
These developments could provide meaningful relief for distinct patient groups. Those with ataxia-telangiectasia, a population with few options, may gain improved disease management and quality of life. Meanwhile, new ADHD therapies could expand choices for patients and clinicians, potentially addressing unmet needs in treatment response or tolerability. However, broader impact will depend on factors such as accessibility, pricing, and long-term real-world evidence. The announcements also signal continued investor and industry interest in specialized therapeutic areas, which may shape future research priorities.